Project Details
Description
MT2021-25: Phase I/II clinical study of GDA-201, allogeneic Natural Killer cells, for patients with relapsed/refractory B-Cell Non-Hodgkin Lymphoma
| Status | Active |
|---|---|
| Effective start/end date | 9/28/21 → 10/1/26 |
Funding
- GAMIDA CELL LTD.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.